Maxcyte, Inc. MXCT
We take great care to ensure that the data presented and summarized in this overview for MAXCYTE, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MXCT
View all-
Cadian Capital Management, LP New York, NY8.23MShares$13 Million0.78% of portfolio
-
Mirabella Financial Services LLP London, X08.2MShares$13 Million0.41% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$12.9 Million0.0% of portfolio
-
Morgan Stanley New York, NY6.7MShares$10.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.59MShares$8.83 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$7.97 Million9.62% of portfolio
-
Mudita Advisors LLP London, X03.37MShares$5.33 Million1.63% of portfolio
-
River & Mercantile Asset Management LLP London, X03.25MShares$5.14 Million2.65% of portfolio
-
Axa Investment Managers S.A. Puteaux, I02.77MShares$4.38 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.56MShares$4.04 Million0.0% of portfolio
Latest Institutional Activity in MXCT
Top Purchases
Top Sells
About MXCT
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Insider Transactions at MXCT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 13
2025
|
William W Brooke |
BUY
Open market or private purchase
|
Direct |
50,000
+24.89%
|
$50,000
$1.29 P/Share
|
|
Aug 13
2025
|
Richard Douglas |
BUY
Open market or private purchase
|
Direct |
80,000
+25.76%
|
$80,000
$1.39 P/Share
|
|
Aug 13
2025
|
Stanley C Erck |
BUY
Open market or private purchase
|
Direct |
100,000
+20.07%
|
$100,000
$1.37 P/Share
|
|
Aug 13
2025
|
Maher Masoud President and CEO |
BUY
Open market or private purchase
|
Direct |
75,000
+30.0%
|
$75,000
$1.37 P/Share
|
|
Aug 13
2025
|
Douglas J Swirsky CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
50,000
+23.61%
|
$50,000
$1.29 P/Share
|
|
Jun 25
2025
|
Rekha Hemrajani |
SELL
Open market or private sale
|
Direct |
10,684
-21.12%
|
$21,368
$2.09 P/Share
|
|
Jun 18
2025
|
John Joseph Johnston |
BUY
Grant, award, or other acquisition
|
Direct |
29,210
+14.58%
|
-
|
|
Jun 18
2025
|
Richard Douglas |
BUY
Grant, award, or other acquisition
|
Direct |
29,210
+16.25%
|
-
|
|
Jun 18
2025
|
Stanley C Erck |
BUY
Grant, award, or other acquisition
|
Direct |
29,210
+8.92%
|
-
|
|
Jun 18
2025
|
Rekha Hemrajani |
BUY
Grant, award, or other acquisition
|
Direct |
29,210
+36.61%
|
-
|
|
Jun 18
2025
|
Patrick J Balthrop |
BUY
Grant, award, or other acquisition
|
Direct |
29,210
+36.61%
|
-
|
|
Jun 18
2025
|
William W Brooke |
BUY
Grant, award, or other acquisition
|
Direct |
29,210
+22.45%
|
-
|
|
Jun 18
2025
|
Cynthia Collins |
BUY
Grant, award, or other acquisition
|
Direct |
29,210
+26.53%
|
-
|
|
Jun 18
2025
|
Yasir B. Al Wakeel |
BUY
Grant, award, or other acquisition
|
Direct |
29,210
+36.61%
|
-
|
|
Mar 18
2025
|
David I. Sandoval GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
353
-0.55%
|
$1,059
$3.18 P/Share
|
|
Mar 18
2025
|
Ali Soleymannezhad Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,211
-2.0%
|
$3,633
$3.18 P/Share
|
|
Mar 18
2025
|
Douglas J Swirsky CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,939
-5.84%
|
$20,817
$3.18 P/Share
|
|
Mar 14
2025
|
Ali Soleymannezhad Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,625
+36.34%
|
-
|
|
Mar 14
2025
|
David I. Sandoval GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
23,125
+26.37%
|
-
|
|
Mar 14
2025
|
Douglas J Swirsky CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+24.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 329K shares |
|---|---|
| Open market or private purchase | 355K shares |
| Exercise of conversion of derivative security | 9K shares |
| Open market or private sale | 32.7K shares |
|---|